As the eye ages, physiological events predispose it to posterior vitreous detachment. This normal ageing process can be complicated by persistent vitreomacular adhesion, which may develop into vitreomacular traction (VMT) accompanied by visual symptoms if forces are great enough to cause macular anatomical changes. Ocriplasmin represents a pharmacological treatment option for VMT resolution.
The vitreoretinal interface is a complex structure that facilitates the attachment between the internal limiting membrane of the retina and the vitreous, a clear gel filling the posterior of the eye. 1, 2 As the eye ages, a series of physiological events occurs to the vitreous, including liquefaction, which predisposes the eye to posterior vitreous detachment (PVD). 2 PVD is a common occurrence in ageing eyes, developing in 75 % of people over the age of 65. 3, 4 PVD is exemplified by the complete separation of the posterior hyaloid membrane from the retinal surface; anomalous PVD represents partial detachment, which can lead to further pathological conditions. The normal process of PVD due to ageing may be complicated by the presence of persistent vitreomacular adhesion (VMA), which occurs when the vitreous cortex adheres to the macula after detaching from the surrounding retina. 2, 3, 5 VMA is typically asymptomatic and is not associated with changes to the macular architecture. However, VMA may develop into vitreomacular traction (VMT), if the forces are great enough to cause observable anatomical changes to the macular architecture. This can result in multiple visual disturbances, such as photopsia, micropsia and metamorphopsia, and can potentially exacerbate concomitant retinal conditions, such as diabetic macular oedema and age-related macular degeneration. 2, [5] [6] [7] Strong or chronic VMT during PVD can result in the development of macular holes. [8] [9] [10] [11] [12] A full-thickness macular hole (FTMH) is a break in the macula that extends through all layers from the internal limiting membrane to the retinal pigment epithelium. 5 A FTMH is rated as small (<250 μm), medium (250-400 μm) and large (>400 μm), based on the recent classification from the International Vitreomacular Traction Study Group. 13 Nearly half of FTMHs are large at the time of detection/diagnosis. 2, 13 An important advance in the understanding and treatment of VMT and FTMH was the development of optical coherence tomography (OCT) technology. OCT provides the basis for greater visualisation of vitreomacular anatomy and has allowed for standardisation in the definitions of VMA, VMT and FTMH. [13] [14] [15] This in turn has provided a more accurate understanding of both retinal anatomy and the pathophysiological processes of VMT and FTMH. 2 The importance of this technology is underscored by the fact that focal VMA can be first discovered on routine examination using OCT. 5, 6, 8, 16 This provides an opportunity to appropriately manage these cases and follow them properly, and to make a decision on when and how to intervene. Use of OCT and standardisation of definitions and treatment algorithms will aid in the development and timing of appropriate treatments. One option for managing patients with VMT (also referred to as symptomatic VMA) involves observation, 15 or watchful waiting, since spontaneous resolution may occur in some cases, and symptoms may be limited in a number of cases. Spontaneous resolution of VMT has been reported to occur between 11-34 % in published studies. 7, [17] [18] [19] [20] [21] [22] [23] [24] However, follow-up periods were extremely long, exceeding 2 years in some cases, with the possibility of visual decline despite successful resolution. 15, 24, 25 For FTMH, reported spontaneous closure rates are on average much lower (3-11 %). 26 Furthermore, most small macular holes progress to medium or large ones, 27 and the likelihood of spontaneous closure drops dramatically after the first year, highlighting the need for intervention. 15, 28 Unlike VMA, extended observation for FTMH is not recommended.
If VMT release does not occur spontaneously, a common and effective treatment option is pars plana vitrectomy. 25, 29, 30 For macular hole closure, vitrectomy is the current standard intervention, with reported macular hole closure rates typically 87.5 % and higher. [31] [32] [33] [34] High visual acuity (VA) improvement rates following vitrectomy are reported, although improvements may be modest (1-2 lines). 25, 35 However, vitrectomy patients require recovery from surgery and a period of post-operative face-down positioning. Additionally, cataract surgery is commonly necessary within the first year after vitrectomy for macular hole repair. Vitrectomy has been associated with complications, such as increased intraocular pressure, risk of infection and others. 14, 28, [35] [36] [37] [38] This has increased the interest in pharmacological vitreolysis, either in conjunction with vitrectomy or as a stand-alone therapy.
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Ocriplasmin Overview and Review of Recent Publications
Ocriplasmin represents a pharmacological treatment option for VMT/ symptomatic VMA. 1, 36 Ocriplasmin is a recombinant truncated form of human plasmin that has proteolytic activity against fibronectin, laminin and collagen, which are present at the vitreoretinal interface and help anchor the vitreous cortex to the retina. 39 Ocriplasmin was approved by the US Food and Drug Administration (FDA) in 2012 after safety and efficacy were established in two phase III clinical trials (MIVI-TRUST 006/007, NCT00781859 and NCT00798317, respectively) involving 652 patients with symptomatic VMA. 40 These large randomised controlled trials assessed the efficacy of a single intravitreal injection of ocriplasmin in patients with VMA/VMT (with or without associated FTMH ≤400 μm).
A total of 26.5 % of eyes receiving ocriplasmin achieved the primary endpoint of VMA/VMT resolution at day 28 compared with 10.1 % of eyes receiving vehicle (p<0.001). 40 These differences did not change substantially at 6 months (26.9 % for the ocriplasmin-treated versus 13.3 % for the vehicle-treated groups; p<0.001). 41 Secondary endpoints were also assessed, and showed a higher percentage of ocriplasmintreated compared with vehicle-treated patients achieving total PVD subgroup but decreased to 39 % in the 'ERM present' subgroup (see Figure 1A ). 26 Singh et al. reported a VMA/VMT resolution rate of 50 % for the 'ERM absent' subgroup versus 33 % for the 'ERM present' subgroup in a study with an overall resolution rate of 47 %. 44 In this study, the focal VMA subgroup showed a resolution of 62 % compared with 0 % for patients with broad VMA (see Figure 1B) . Kim et al. reported a resolution rate for the 'FTMH present' subgroup as 67 %, but only 31 % for the 'FTMH absent' subgroup (see Figure 1C) . 43 Even studies with high overall VMT resolution rates showed subgroup favourability. For instance, Willekens et al. reported an overall VMT resolution rate of 71 %; this rate is exceeded in every subgroup (see Figure 1A -C), and eyes meeting three criteria showed a resolution rate of 84 %. These results confirm that patient selection influences the assessment of ocriplasmin efficacy for VMA/VMT resolution.
In addition to VMA/VMT resolution, the efficacy of ocriplasmin for FTMH closure was assessed. In the clinical trials, closure rates were 40.6 % for ocriplasmin-treated versus 10.6 % for vehicle-treated patients at day 28, and remained high at the end of the study (40.6 % versus 17.0 %, respectively). 40, 41 Among the 26 studies, 22 reported FTMH closure rates (see Table 1 ). Of these, 13 reported study group averages before and after ocriplasmin treatment, with the vast majority (12) reporting mean VA improvement 26, 44, 45, 48, 50, [53] [54] [55] [56] [57] 59, 62 and one reporting VA decline (see Figure 3) . 63 Study follow-up times ranged from 19 days to 8.7 months.
Three of 18 studies reported VA improvement in a subset of patients; two studies showed VA improvement in patients who achieved VMA/ VMT release, 1, 60 and one study showed patient VA improvement following FTMH closure, but not for patients without FTMH closure. 15 cases with analysable VA data. [68] [69] [70] [71] [72] [73] [74] [75] [76] 79, 80, 82, 83 Ten of these 15 (66.7 %) reported improved VA results. 70, [73] [74] [75] [76] 79, 80, 83 Patients showing improvement were followed anywhere from 28 days to 15 months. Only three of the five cases not reporting VA improvement provided a follow-up length longer than 9 days. Of these, the longest reported follow-up period was 4 months. 71, 72, 82 Importantly, of the 10 cases reporting VA improvement at the final follow-up, six (60 %) showed interim VA decline. [73] [74] [75] 79, 80, 83 This suggests that efficacy regarding VA improvement is closely related to the length of time patients are followed and reported on.
Discussion
Three The full clinical picture of ocriplasmin efficacy will be determined through continued and consistent reporting and data analysis.
Accurate analysis, including study averages, as well as subgroups and collective case reports, will help further identify ideal candidates for ocriplasmin treatment. n
